Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

Author: HildrethS W, HogermanD A, MoharC K, ParadisoP, TristramD A, WelliverR C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that a subunit vaccine for respiratory syncytial virus (RSV) was safe and effective in children who had previously been infected with RSV. The vaccine was effective at preventing infection in these children.
Paper Details　
Original Abstract of the Article :
Twenty-six children (aged 18-36 months) previously hospitalized for respiratory syncytial virus (RSV) infection were randomized to receive 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein or saline placebo by intramuscular injection. Serum was obtained at entry and at 1 a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/167.1.191

データ提供：米国国立医学図書館（NLM）

A Subunit Vaccine for Respiratory Syncytial Virus: Hope for Immune Children

The quest for an effective vaccine against respiratory syncytial virus (RSV) has been as elusive as finding a hidden oasis in a vast desert. This study investigated the immunogenicity and safety of a subunit vaccine composed primarily of the F glycoprotein in children aged 18-36 months who had previously been hospitalized for RSV infection. The researchers evaluated the vaccine's ability to stimulate an immune response and assessed its safety in this vulnerable population.

Promising Results for a Subunit RSV Vaccine

The study demonstrated that the subunit F protein vaccine was both safe and immunogenic, leading to significant increases in antibody titers against RSV in the vaccinated children. Importantly, no vaccine recipient experienced RSV infection in the six months following vaccination, suggesting that the vaccine may offer protection against future infections, much like a well-stocked oasis providing sustenance in a harsh landscape.

A Ray of Hope in the Desert of RSV

This research provides a glimmer of hope in the ongoing battle against RSV. The findings suggest that a subunit F protein vaccine could offer a safe and effective means of protecting children from this common and potentially serious respiratory illness, offering a much-needed oasis in the desert of RSV research.

Dr.Camel's Conclusion

This study, like a refreshing spring in the desert, brings hope for a safe and effective vaccine against RSV. The promising results suggest that the subunit F protein vaccine may provide a shield against future RSV infections, offering a valuable resource for children who have already experienced the harsh realities of this respiratory illness. Further research is needed to confirm these findings and explore the long-term effectiveness of this vaccine, but this study is a significant step forward in the quest for a lasting solution to RSV.

Date :
  1. Date Completed 1993-02-02
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

8418166

DOI: Digital Object Identifier

10.1093/infdis/167.1.191

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.